AU2023317864A1 - Intranasal administration of ngf for the treatment of sensorineural hearing loss - Google Patents
Intranasal administration of ngf for the treatment of sensorineural hearing loss Download PDFInfo
- Publication number
- AU2023317864A1 AU2023317864A1 AU2023317864A AU2023317864A AU2023317864A1 AU 2023317864 A1 AU2023317864 A1 AU 2023317864A1 AU 2023317864 A AU2023317864 A AU 2023317864A AU 2023317864 A AU2023317864 A AU 2023317864A AU 2023317864 A1 AU2023317864 A1 AU 2023317864A1
- Authority
- AU
- Australia
- Prior art keywords
- ngf
- seq
- mutein
- treatment
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011891 Deafness neurosensory Diseases 0.000 title claims abstract description 32
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 title claims abstract description 32
- 231100000879 sensorineural hearing loss Toxicity 0.000 title claims abstract description 32
- 208000023573 sensorineural hearing loss disease Diseases 0.000 title claims abstract description 32
- 108010025020 Nerve Growth Factor Proteins 0.000 claims abstract description 83
- 102000015336 Nerve Growth Factor Human genes 0.000 claims abstract description 78
- 229940053128 nerve growth factor Drugs 0.000 claims abstract description 76
- 230000002265 prevention Effects 0.000 claims abstract description 15
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims description 27
- 102000046917 human NGF Human genes 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 229920001993 poloxamer 188 Polymers 0.000 claims description 15
- 229960004452 methionine Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 230000032683 aging Effects 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- 231100000199 ototoxic Toxicity 0.000 claims description 5
- 230000002970 ototoxic effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 241001465754 Metazoa Species 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 22
- 208000016354 hearing loss disease Diseases 0.000 description 16
- 206010011878 Deafness Diseases 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000003027 ear inner Anatomy 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 231100000888 hearing loss Toxicity 0.000 description 11
- 230000010370 hearing loss Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
- 229930195722 L-methionine Natural products 0.000 description 10
- 210000002768 hair cell Anatomy 0.000 description 10
- 210000000067 inner hair cell Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000003477 cochlea Anatomy 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 102000011383 Prestin Human genes 0.000 description 8
- 108050001617 Prestin Proteins 0.000 description 8
- 235000019799 monosodium phosphate Nutrition 0.000 description 8
- 210000004049 perilymph Anatomy 0.000 description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 8
- 238000005063 solubilization Methods 0.000 description 8
- 230000007928 solubilization Effects 0.000 description 8
- 210000000225 synapse Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000009758 senescence Effects 0.000 description 6
- 102000007072 Nerve Growth Factors Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000000860 cochlear nerve Anatomy 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 210000000959 ear middle Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 210000003030 auditory receptor cell Anatomy 0.000 description 4
- 230000006727 cell loss Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 241000197194 Bulla Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 208000002352 blister Diseases 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 231100000890 cochlea damage Toxicity 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000001323 spiral ganglion Anatomy 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- PBJBVIHLBRYRQC-UHFFFAOYSA-N 1-o-[2-(diethylamino)ethyl] 3-o-ethyl 2-methyl-2-phenylpropanedioate Chemical compound CCN(CC)CCOC(=O)C(C)(C(=O)OCC)C1=CC=CC=C1 PBJBVIHLBRYRQC-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000016621 Hearing disease Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 210000002985 organ of corti Anatomy 0.000 description 2
- 238000011422 pharmacological therapy Methods 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000013707 sensory perception of sound Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 230000005788 Cochlea function Effects 0.000 description 1
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 1
- 206010010280 Conductive deafness Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032041 Hearing impaired Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102100035276 Prestin Human genes 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 108091006506 SLC26A5 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000014646 age-related hearing impairment Diseases 0.000 description 1
- 230000001618 algogenic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000023563 conductive hearing loss disease Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- BBKFSSMUWOMYPI-UHFFFAOYSA-N gold palladium Chemical compound [Pd].[Au] BBKFSSMUWOMYPI-UHFFFAOYSA-N 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 108091008704 mechanoreceptors Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000012005 synaptopathy Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22188990.0A EP4316505A1 (en) | 2022-08-05 | 2022-08-05 | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| EP22188990.0 | 2022-08-05 | ||
| PCT/EP2023/071698 WO2024028487A1 (en) | 2022-08-05 | 2023-08-04 | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023317864A1 true AU2023317864A1 (en) | 2025-02-13 |
Family
ID=82846594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023317864A Pending AU2023317864A1 (en) | 2022-08-05 | 2023-08-04 | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP4316505A1 (https=) |
| JP (1) | JP2025525989A (https=) |
| CN (1) | CN119836297A (https=) |
| AU (1) | AU2023317864A1 (https=) |
| CA (1) | CA3263975A1 (https=) |
| IL (1) | IL318657A (https=) |
| WO (1) | WO2024028487A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4659759A1 (en) * | 2024-06-04 | 2025-12-10 | Dompé farmaceutici SpA | Administration of ngf for the treatment of niemann-pick type c disease |
| WO2026022244A1 (en) | 2024-07-23 | 2026-01-29 | Chiesi Farmaceutici S.P.A. | A polypeptide for use in the therapeutic management of acute ischaemic stroke |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2213861T3 (es) | 1998-10-09 | 2004-09-01 | Scil Proteins Gmbh | Procedimiento de obtencion de ngf-beta activa. |
| ITRM20110390A1 (it) * | 2011-07-21 | 2013-01-22 | Eramo Alessandra D | Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione. |
| CN104203264B (zh) | 2011-12-19 | 2018-08-28 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
| WO2017120465A1 (en) * | 2016-01-06 | 2017-07-13 | Massachusetts Eye And Ear Infirmary | Treating cochlear synaptopathy |
| WO2018140792A2 (en) * | 2017-01-27 | 2018-08-02 | Otonomy, Inc. | Neurotrophin mutants for treating hearing loss and other otic disorders |
| EP3406259A1 (en) * | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| MA52351A (fr) | 2018-04-27 | 2021-05-26 | Chiesi Farm Spa | Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci |
| CN114829384B (zh) * | 2020-11-19 | 2023-12-12 | 舒泰神（北京）生物制药股份有限公司 | 长效神经生长因子多肽及其用途 |
-
2022
- 2022-08-05 EP EP22188990.0A patent/EP4316505A1/en not_active Withdrawn
-
2023
- 2023-08-04 WO PCT/EP2023/071698 patent/WO2024028487A1/en not_active Ceased
- 2023-08-04 IL IL318657A patent/IL318657A/en unknown
- 2023-08-04 EP EP23757837.2A patent/EP4565255A1/en active Pending
- 2023-08-04 AU AU2023317864A patent/AU2023317864A1/en active Pending
- 2023-08-04 CA CA3263975A patent/CA3263975A1/en active Pending
- 2023-08-04 JP JP2025507000A patent/JP2025525989A/ja active Pending
- 2023-08-04 CN CN202380063408.0A patent/CN119836297A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119836297A (zh) | 2025-04-15 |
| EP4316505A1 (en) | 2024-02-07 |
| EP4565255A1 (en) | 2025-06-11 |
| IL318657A (en) | 2025-03-01 |
| CA3263975A1 (en) | 2024-02-08 |
| WO2024028487A1 (en) | 2024-02-08 |
| JP2025525989A (ja) | 2025-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12102692B2 (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| US20230330268A1 (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| WO2024028487A1 (en) | Intranasal administration of ngf for the treatment of sensorineural hearing loss | |
| Hu et al. | NGF stimulates extensive neurite outgrowth from implanted dorsal root ganglion neurons following transplantation into the adult rat inner ear | |
| EP3406259A1 (en) | Neurotrophins for use in the treatment of hearing loss | |
| US20260048006A1 (en) | Intranasal administration of bdnf for the treatment of sensorineural hearing loss | |
| US12390510B2 (en) | Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2) | |
| US7390482B2 (en) | Drug for auditory dysfunction | |
| US8691765B2 (en) | Metallothionein based neuronal therapeutic and therapeutic methods | |
| US20110207689A1 (en) | The treatment of hearing loss | |
| HK40074395A (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| Galindo | The effect of neurotrophic factors on spiral ganglion neurons | |
| HK40003977B (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| HK1262434B (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |